Teva, Active Biotech halt higher doses of oral MS drug in trials

January 4, 2016 2:27 PM

13 0

JERUSALEM Jan 4 Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients.

Both trials of laquinimod will continue with the lower dose of 0.6 mg daily where there were no issues.

Also read: Merck's antiviral drug meets main goal in late-stage trial

Read more

To category page